[1]朱萍,卫红艳,王坤玲,等.Graves病甲状腺功能亢进症性肝损害的 相关因素分析[J].国际内分泌代谢杂志,2017,37(03):164-167.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
　Zhu Ping,Wei Hongyan,Wang Kunling,et al.Related factors of hyperthyroidism-related liver dysfunction in Graves' disease[J].International Journal of Endocrinology and Metabolism,2017,37(03):164-167.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
点击复制

Graves病甲状腺功能亢进症性肝损害的 相关因素分析()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
37
期数:
2017年03期
页码:
164-167
栏目:
短篇论著
出版日期:
2017-05-20

文章信息/Info

Title:
Related factors of hyperthyroidism-related liver dysfunction in Graves' disease
作者:
朱萍; 卫红艳; 王坤玲; 汤绍芳; 马中书
300052 天津医科大学总医院内分泌代谢科
Author(s):
Zhu Ping;  Wei Hongyan;  Wang Kunling;  Tang Shaofang;  Ma Zhongshu.
Department of Endocrinology and Metabolism, The General Hospital, Tianjin Medical University,Tianjin 300052,China
关键词:
Graves病;  甲状腺功能亢进症;  肝功能损害;  甲状腺激素
Keywords:
Graves' disease;  Hyperthyroidism;  Liver dysfunction;  Thyroid hormone
DOI:
10.3760/cma.j.issn.1673-4157.2017.03.005
摘要:
目的 探讨影响Graves病甲状腺功能亢进症(甲亢)性肝功能损害的相关因素。方法 回顾性分析天津医科大学总医院2013年1月至2015年12月收治的Graves病住院患者254例,根据肝功能将患者分为Graves病甲亢性肝损害组(A组,n=159)和甲亢肝功能正常组(B组,n=95),比较两组的基础代谢率(BMR)、甲状腺重量、FT3、FT4、促甲状腺激素(TSH)、TSH受体抗体(TRAb)、甲状腺球蛋白抗体(TgAb)、甲状腺过氧化物酶抗体(TPOAb)。采用Pearson相关性分析甲状腺重量、BMR、FT3、FT4、TRAb与甲亢性肝损害的相关性,应用Logistic回归分析甲亢性肝损害的独立危险因素。结果A组的甲状腺重量、BMR、FT3、FT4、TRAb、TPOAb均高于B组,而TSH低于B组(t或z=-4.720～-2.276,P均<0.05)。Pearson相关性分析显示,甲状腺重量、BMR、FT3、FT4、TRAb与甲亢性肝损害的发生呈正相关(r=0.157～0.270,P均<0.05)。Logistic回归分析显示,FT3(OR=1.052,95% CI:1.001～1.105)、BMR(OR=1.019,95% CI:1.006～1.033)是Graves病甲亢性肝损害发生的独立危险因素(P均<0.05)。结论 Graves病甲亢性肝损害与FT3、FT4、TRAb、BMR、甲状腺重量有关。其中FT3、BMR为甲亢性肝损害发生的独立危险因素。
Abstract:
Objective To investigate the related factors of hyperthyroidism-related liver dysfunction in Graves' disease.Methods A total of 254 patients with Graves' disease hospitalized in the General Hospital of Tianjin Medical University from January 2013 to December 2015 were enrolled and divided into two groups based on liver function: Graves' disease with abnormal liver function group(group A, n=159), and normal hepatic function group(group B, n=95). The basal metabolic rate(BMR), weight of thyroid gland, FT3, FT4, thyroid-stimulating hormone(TSH), anti-thyrotrophin receptor antibody(TRAb), thyroglobulin antibody(TgAb), anti-thyroid peroxidase antibody(TPOAb)were compared between the two groups. Pearson correlation was used to analyze the correlation between thyroid weight, BMR, FT3, FT4, TRAb and hyperthyroidism-related liver dysfunction. Logistic regression was used to analyze the independent risk factors of hyperthyroidism-related liver function.Results The weight of thyroid gland, BMR, FT3, FT4, TRAb and TPOAb in group A were higher than those in group B, while TSH in group A was lower than that in group B(t or z=-4.720--2.276, all P<0.05). Pearson correlation analysis showed that hyperthyroidism-related liver dysfunction was positively related to the weight of thyroid gland, BMR, FT3, FT4 and TRAb(r=0.157-0.270, all P<0.05). Logistic regression analysis showed that FT3(OR=1.052, 95% CI:1.001-1.105)and BMR(OR=1.019, 95% CI:1.006-1.033)were the independent risk factors for hyperthyroidism-related liver dysfunction in Graves' disease(all P<0.05).Conclusion The risk factors of hyperthyroidism-related liver dysfunction in Graves' disease include weight of thyroid gland, BMR, FT3, FT4 and TRAb. BMR and FT3 are the independent risk factors for hyperthyroidism-related liver dysfunction in Graves' disease.

参考文献/References:

[1] Khemichian S, Fong TL. Hepatic dysfunction in hyperthyroidism[J].Gastroenterol Hepatol(N Y),2011,7(5):337-339.
[2] Lo CM. Liver transplantation for acute liver failure: not too early but never too late[J].Liver Transpl,2008,14(9):1243-1244. DOI:10.1002/lt.21536.
[3] 滕卫平.甲状腺功能亢进症//葛均波, 徐永健主编. 内科学[M].第8版.北京:人民卫生出版社, 2013.685-692.
[4] Perry RJ, Hollman AS, Wood AM,et al. Ultrasound of the thyroid gland in the newborn: normative data[J].Arch Dis Child Fetal Neonatal Ed,2002,87(3):F209-F211.
[5] Youssef WI, Mullen KD. The liver in other(nondiabetic)endocrine disorders[J].Clin Liver Dis,2002,6(4):879-889.
[6] Kubota S, Amino N, Matsumoto Y,et al. Serial changes in liver function tests in patients with thyrotoxicosis induced by Graves' disease and painless thyroiditis[J].Thyroid,2008,18(3):283-287. DOI:10.1089/thy.2007.0189.
[7] 赵家军. 甲状腺疾病与肝脏[J]. 中华肝脏病杂志, 2014, 22(3): 165-167. DOI:10.3760/cma.j.issn.1007-3418.2014.03.002.
[8] 刘然, 杨倩琳, 赵丽, 等. 1221例未治疗成年Graves病患者肝功能指标异常情况及相关因素分析[J]. 中华内分泌代谢杂志,2015, 31(6): 497-500. DOI:10.3760/cma.j.issn.1000-6699.2015.06.005.
[9] Shen C, Zhao CY, Liu F,et al. Acute-on-chronic liver failure due to thiamazole in a patient with hyperthyroidismand trilogy of Fallot: case report[J].BMC Gastroenterol,2010,10:93. DOI:10.1186/1471-230X-10-93.
[10] 李承霞, 谭建, 张桂芝, 等. 回顾性研究:甲状腺机能亢进症伴肝功能损害危险因素分析[J]. 中华内分泌代谢杂志, 2015, 31(6): 501-505. DOI:10.3760/cma.j.issn.1000-6699.2015.06.006.
[11] 任留梅, 刘萍, 卫红艳, 等. Graves病甲亢肝损害与免疫因素关系的探讨[J]. 实用医学杂志, 2011, 27(3): 436-438.DOI:10.3969/j.issn.1006-5725.2011.03.029.
[12] de Campos Mazo DF, de Vasconcelos GB, Pereira MA,et al. Clinical spectrum and therapeutic approach to hepatocellular injury in patients with hyperthyroidism[J].Clin Exp Gastroenterol,2013,6:9-17. DOI: 10.2147/CEG.S39358.
[13] Woeber KA. Methimazole-induced hepatotoxicity[J].Endocr Pract,2002,8(3):222-224. DOI:10.4158/EP.8.3.222.
[14] Malik R, Hodgson H. The relationship between the thyroid gland and the liver[J].QJM,2002,95(9):559-569.
[15] Zhang W, Tian LM, Han Y, et al. Presence of thyrotropin receptor in hepatocytes: not a case of illegitimate transcription[J].J Cell Mol Med,13(11-12):4636-4642. DOI: 10.1111/j.1582-4934.2008.00670.x.

相似文献/References:

[1]陈晓铭 胡卓清 李潍 刘美莲 吴美芬 方烁 武革.CD40-1C/T多态性（rs1883832）与粤西汉族人Graves病的关系[J].国际内分泌代谢杂志,2015,(01):11.[doi:10.3760/cma.j.issn.1673-4157.2015.01.003]
　Chen Xiaoming,Hu Zhuoqing,Li Wei,et al.Relationship between CD40-1C/T polymorphism（rs1883832）and Graves′ disease of Han population in western region of Guangdong province[J].International Journal of Endocrinology and Metabolism,2015,(03):11.[doi:10.3760/cma.j.issn.1673-4157.2015.01.003]
[2]赵永强,田德增,魏晓华,等.不同治疗方法对Graves病患者外周血淋巴细胞亚群的影响[J].国际内分泌代谢杂志,2015,(04):234.[doi:10.3760/cma.j.issn.1673-4157.2015.04.005]
　Zhao Yongqiang*,Tian Dezeng,Wei Xiaohua,et al.Effects of different therapeutic methods on peripheral blood lymphocyte subgroups in patients with Graves' disease[J].International Journal of Endocrinology and Metabolism,2015,(03):234.[doi:10.3760/cma.j.issn.1673-4157.2015.04.005]
[3]瞿茹怡,李圣贤,陆咏,等.2q33区基因多态性与Graves病发病风险的研究[J].国际内分泌代谢杂志,2014,(02):77.[doi:10.3760/cma.j.issn.1673-4157.2014.02.002]
　Qu Ruyi*,Li Shengxian,Lu Yong,et al.Association between 2q33 gene polymorphism and Graves' disease[J].International Journal of Endocrinology and Metabolism,2014,(03):77.[doi:10.3760/cma.j.issn.1673-4157.2014.02.002]
[4]朱丹,陈国芳,刘超,等.糖尿病患者合并甲状腺功能异常的机制 及其影响[J].国际内分泌代谢杂志,2016,36(03):206.[doi:10.3760/cma.j.issn.1673-4157.2016.03.16]
　Zhu Dan*,Chen Guofang,Liu Chao,et al.Mechanisms of diabetes combined with thyroid dysfunction and its influence[J].International Journal of Endocrinology and Metabolism,2016,36(03):206.[doi:10.3760/cma.j.issn.1673-4157.2016.03.16]
[5]韩煦,魏军平.促甲状腺激素受体抗体的检测及其在Graves病 诊疗中的价值[J].国际内分泌代谢杂志,2017,37(02):94.[doi:10.3760/cma.j.issn.1673-4157.2017.02.006]
　Han Xu,Wei Junping..Thyroid stimulating hormone receptor antibodies assays and its clinical significance in Graves' disease[J].International Journal of Endocrinology and Metabolism,2017,37(03):94.[doi:10.3760/cma.j.issn.1673-4157.2017.02.006]
[6]刘燕晶 张帆.甲状腺功能亢进症性肝损害的发生机制[J].国际内分泌代谢杂志,2019,39(01):34.[doi:10.3760/cma.j.issn.1673-4157.2019.01.008]
　Liu Yanjing,Zhang Fan.The pathogenesis of liver damage of hyperthyroidism[J].International Journal of Endocrinology and Metabolism,2019,39(03):34.[doi:10.3760/cma.j.issn.1673-4157.2019.01.008]
[7]马金刚 魏红丽 尚恒.Graves病患者外周血T细胞亚群与甲状腺 功能及甲状腺自身抗体间的相关性分析[J].国际内分泌代谢杂志,2020,40(01):21.[doi:10.3760/cma.j.issn.1673-4157.2020.01.005]
　Ma Jingang,Wei Hongli,Shang Heng.Correlation between peripheral blood T cell subsets and thyroid function and thyroid autoantibodies in patients with Graves' disease[J].International Journal of Endocrinology and Metabolism,2020,40(03):21.[doi:10.3760/cma.j.issn.1673-4157.2020.01.005]
[8]姚瑶,郑仁东,刘超.血浆置换治疗甲状腺功能亢进症的研究进展[J].国际内分泌代谢杂志,2020,40(05):320.[doi:10.3760/cma.j.cn121383-20191218-12047]
　Yao Yao,Zheng Rendong,Liu Chao.Update on plasmapheresis for hyperthyroidism[J].International Journal of Endocrinology and Metabolism,2020,40(03):320.[doi:10.3760/cma.j.cn121383-20191218-12047]
[9]刘天琪,张秀英,纪立农.促甲状腺激素受体抗体的检测及应用进展[J].国际内分泌代谢杂志,2021,41(01):5.[doi:10.3760/cma.j.cn121383-20200608-06021]
　Liu Tianqi,Zhang Xiuying,Ji Linong..Progression of assay and clinical practice of thyroid stimulating hormone receptor antibody[J].International Journal of Endocrinology and Metabolism,2021,41(03):5.[doi:10.3760/cma.j.cn121383-20200608-06021]
[10]陈莹 倪文婧 陈国芳 徐书杭.基于复发危险因素探讨Graves病治疗的新策略[J].国际内分泌代谢杂志,2022,42(04):260.[doi:10.3760/cma.j.cn121383-20210412-04031]
　Chen Ying,Ni Wenjing,Chen Guofang,et al.New strategies for the treatment of Graves' disease based on risk factors of relapse[J].International Journal of Endocrinology and Metabolism,2022,42(03):260.[doi:10.3760/cma.j.cn121383-20210412-04031]

备注/Memo

备注/Memo:
通信作者:马中书,Email:zhongshuma@sina.com
更新日期/Last Update: 2017-05-20